Adepthera LLC
Palo Alto, CA
- UEI
- QDWUGUNKHMT5
- CAGE
- 6M1S1
- Primary NAICS
- 325412 Pharmaceutical Preparation Manufacturing
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- NAICS codes registered in SAM.gov
- SAM.gov registration date
- Physical address
- 3353 Alma St #245, Palo Alto, CA 94306, USA
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Regenerative peptide therapy to accelerate pressure ulcer healing - abstract adrenomedullin (ADM) and cgrp family… | National Institute on Aging | $367,000 | |
| A therapy for improving diabetic ulcer healing - diabetic ulcer is one of the major complications of diabetes mellitus… | National Institute of Diabetes and Digestive and Kidney Diseases | $335,342 | |
| Development of a treatment-resistant hypertension (rhtn) depot therapeutics | National Heart Lung and Blood Institute | $338,152 | |
| Development of a novel anti-migraine therapeutics | National Institute of Neurological Disorders and Stroke | $248,910 | |
| Novel therapeutics for endothelial dysfunction | National Center for Advancing Translational Sciences | $290,425 |
About Adepthera LLC
Adepthera LLC is a for-profit limited liability company that has been registered in SAM.gov to receive federal contract and grant awards since September 2012. The company appears to specialize in developing novel therapeutics and drug delivery systems for various diseases and conditions.
Through its federal grant awards, Adepthera LLC has primarily focused on developing innovative therapies for chronic conditions such as diabetes, hypertension, and migraines. In a recent grant from the National Institute of Diabetes and Digestive and Kidney Diseases, the company received $335,342 to develop a novel gel therapy for accelerating wound healing in diabetes patients. This project aims to identify an optimal gel formulation that provides sustained and localized treatment, and investigate the efficacy of the selected analog gel on wound healing in rodent diabetic ulcer models. The company has also received funding from the National Heart Lung and Blood Institute for the development of a treatment-resistant hypertension (RHTN) depot therapeutics ($338,152), and from the National Institute of Neurological Disorders and Stroke for the development of a novel anti-migraine therapeutics ($248,910). These grants highlight Adepthera LLC's focus on developing innovative drug delivery systems and therapies for chronic diseases through federally funded research programs in the Department of Health and Human Services.
Quick answers
What is Adepthera LLC's UEI?
Adepthera LLC's Unique Entity ID (UEI) in SAM.gov is QDWUGUNKHMT5.
What is Adepthera LLC's CAGE code?
Adepthera LLC's CAGE code is 6M1S1.
What is Adepthera LLC's primary NAICS code?
Adepthera LLC's primary NAICS code is 325412 (Pharmaceutical Preparation Manufacturing).
Where is Adepthera LLC located?
Adepthera LLC's physical address in SAM.gov is 3353 Alma St #245, Palo Alto, CA 94306, USA.
Is Adepthera LLC registered in SAM.gov?
Yes. Adepthera LLC's SAM.gov registration is active through March 18, 2027.
What is Adepthera LLC's most recent federal award?
Adepthera LLC's most recent federal grant award is Regenerative peptide therapy to accelerate pressure ulcer healing - abstract adrenomedullin (ADM) and cgrp family… (R43AG090115), from National Institute on Aging, on September 15, 2024.
On GovTribe
See Adepthera LLC's full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors